Bristol Myers Squibb vs. Johnson & Johnson: Which Healthcare Stock Is a Better Buy in 2026?
Revisiting Stock Picks Intel, Progressive, Bristol Myers Squibb
Bristol Myers Squibb (BMY) Ascends While Market Falls: Some Facts to Note
3 Reasons to Buy Bristol Myers Squibb Stock
Bristol Myers Squibb to Report Results for Second Quarter 2026 on July 30, 2026
Bristol Myers Squibb Announces Dividend
Elicio Therapeutics Points To Durable Responses As It Maps Next Steps For Lead Cancer Drug
The Healthcare M&A Wave
3 Stocks to Invest In to Rebalance Your Portfolio
Investors Heavily Search Bristol Myers Squibb Company (BMY): Here is What You Need to Know
Interest Rates Are Going Higher: 4 High-Yield Passive Income Stocks Can Weather Any Storm
Can BMY's Camzyos Strengthen Its Cardiovascular Portfolio?
3 Dividend Stocks to Hold for the Long Haul
A Dramatic Shift in Fed Policy Just Unlocked a New Era for Bristol Myers Squibb
How Safe is Bristol Myers Squibb's Dividend? Here's My Honest Take.
Can Bristol Myers' Growth Portfolio Offset Legacy Drug Declines?
Why Bristol Myers Squibb (BMY) Outpaced the Stock Market Today
Bristol Myers Squibb Dividend Raise Streak is 18 Years. Here's 1 Number That Says the Streak Will Continue.
Bristol Myers Squibb (BMY) is a Top-Ranked Value Stock: Should You Buy?
Takeda's AI-crafted psoriasis pill tops Bristol Myers' Sotyktu in head-to-head trial
Bristol-Myers Squibb Company (BMY) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Mariska Hargitay Partners with Bristol Myers Squibb for “Investigating Myeloma” Awareness Campaign to Honor Her Father 20 Years After Losing Him to the Disease
Bristol Myers Squibb (BMY) Gains As Market Dips: What You Should Know
Billionaire Izzy Englander Just Made a Big Bet on This Beaten-Down High-Yield Dividend Stock
Arcus, Bristol Myers Team Up to Advance Kidney Cancer Study
Better High-Yield Dividend Stock to Buy: Bristol Myers Squibb or Pfizer?
Bristol Myers Squibb Company (BMY) is Attracting Investor Attention: Here is What You Should Know
Arcus Biosciences Announces Clinical Trial Collaboration and Supply Agreement to Evaluate Casdatifan in Combination with PD‑L1/VEGF‑A Bispecific Immunomodulator to Treat Kidney Cancer
Bristol Myers vs. Pfizer: Which High‑Yield Dividend Stock Wins Now?
Recursion Pharmaceuticals vs. Schrödinger: Which Healthcare Stock Is a Better Buy in 2026?
BMY Gets Opdivo Label Expansion in the EU, Update on Camzyos
Bristol Myers Squibb: This Pullback Is A Gift For Long-Term Investors
Izalontamab Brengitecan (Iza-Bren) Demonstrates Statistically Significant and Clinically Meaningful Improvements in Overall Survival and Progression-Free Survival in Patients with Triple-Negative Breast Cancer and Esophageal Squamous Cell Carcinoma
Bristol Myers' Growth Portfolio Just Overtook The Legacy One
Why Bristol Myers Squibb Stock Isn't Nearly As Cheap As It Looks
Bristol Myers Showcases Data on MM and NSCLC Drugs at ASCO
U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb's Supplemental New Drug Application for Camzyos (mavacamten) to Treat Adolescents with Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM)
Bristol Myers Squibb Announces Opdivo® (nivolumab) in Combination with AVD Receives Expanded EU Label with Approval in Frontline Advanced Classical Hodgkin Lymphoma
Global Data for BioNTech and Bristol Myers Squibb’s PD-L1xVEGF-A Bispecific Pumitamig Shows Encouraging Efficacy in Patients with Non-Small Cell Lung Cancer in ROSETTA Lung-02 Trial
Globale Daten der ROSETTA Lung-02-Studie: Ermutigende Wirksamkeit für BioNTechs und Bristol Myers Squibbs bispezifischen PD-L1xVEGF-A-Immunmodulator-Kandidat Pumitamig bei nicht-kleinzelligem Lungenkrebs
Bristol Myers drug delays myeloma progression in hard to treat patients
How Bristol Is Building On Its $74 Billion Celgene Buyout With New 'Molecular Glue'
Bristol Myers Squibb Announces CELMoD Mezigdomide Reduces Risk of Disease Progression or Death by More than 50% vs. Standard of Care in Relapsed or Refractory Multiple Myeloma
Bristol-Myers Squibb Is Quietly Building Its Next Growth Cycle
Bristol Myers Squibb to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference
Here's Why Bristol Myers Squibb (BMY) is a Strong Value Stock
Looking to Buy Bristol Myers Squibb Stock on the Dip? Read This First.
Bristol Myers Squibb to Unveil New Data at ASCO® 2026 Demonstrating Strength and Breadth of Scientific Innovation Across Oncology Portfolio and Next-Generation Pipeline
The Most Undervalued Healthcare Stock in the S&P 500 Right Now
Bristol Myers to deploy Anthropic's Claude AI model to speed up drug discovery